NL-OMON42626已完成不适用
An open-label, two-way cross-over, randomized study to assess the pharmacokinetics and safety/tolerability of intra-vaginal delivery of gonadorelin and oxybutynin in healthy female volunteers - Pharmacokinetics of intravaginal drug delivery
iGalli BV0 个研究点目标入组 6 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Healthy female subjects aged between 18 and 40 years (inclusive)
- •2. Body mass index between 18-32 kg*m2 (inclusive);
- •3. Using oral contraceptives of second generation containing ethinylestradiol and progesterone derivate.
排除标准
- •1. Clinically significant abnormalities in laboratory test, vital signs and ECG
- •2. Being a virgin.
- •3. History of sexual abuse/violence.
- •4. Being pregnant or breast feeding
研究者
相似试验
已完成
1 期
A randomized, open-label and two-way crossover study to evaluate the effects of SIR1-365 after a single oral dose of 300 mg on the activities of CYP450 isoform 3A in healthy young subjectsACTRN12621000400864Sironax Australia Pty Ltd20
进行中（未招募）
1 期
A study in healthy volunteers to compare the test medicine as both a tablet and capsule, to determine the correlation between increases in doses of the test medicine and the amount of test medicine taken up by the body, and to estimate how food affects the test medicine when given as a tabletInflammatory bowel disease (IBD), respiratory diseases including chronic obstructive pulmonary disease (COPD) and severe asthma, and Parkinson’s diseaseISRCTN14438276F. Hoffmann-La Roche Ltd31
已完成
不适用
A randomized, single-site, open-label, 2-way crossover, single-dose Phase I clinical trial to assess the bioequivalence of 2 tablets of a tapentadol 25 mg prolonged-release tablet formulation and 1 tablet of a tapentadol 50 mg prolonged-release tablet formulation in healthy male subjects under fed conditionschronische pijn bij volwassenenchronic pain in adultsNL-OMON46632Grünenthal GmbH40
进行中（未招募）
1 期
A randomized, open label, two-way crossover study investigating the relative bioavailability of a single 5 mg dose of everolimus administered as either 5x1 mg everolimus intact tablets or 5x1 mg everolimus tablets suspended in 30 mL of water to healthy subjectsHealthy volunteersEUCTR2012-000299-40-Outside-EU/EEAovartis Pharma Services AG40
已完成
不适用
Evaluation of Pharmacokinetic/Pharmacodynamic Properties and Safety of Leucostim® Compared to Neupogen® in Healthy Adult VolunteersDiseases of the blood and blood -forming organs and certain disorders involving the immune mechanismKCT0001861Dong-A ST56